shutterstock_1089215192_jhvephoto

jhvephoto / Shutterstock.com

15 April 2019Americas

Fresenius files IPR against Amgen

Fresenius Kabi has submitted a petition for inter partes review (IPR) of US patent number 9,856,287, a patent owned by Amgen.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen wins biosimilars case against Apotex at Federal Circuit

6 July 2016 The US Court of Appeals for the Federal Circuit ruled yesterday in the Amgen v Apotex case that bisoimilars companies must always notify brand name rivals 180 days before launching their products.

Sanofi victorious at Fed Circ in prostate cancer drug dispute

15 August 2019 Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.

Fresenius in patent dispute over hypocalcemia treatment

7 December 2021 Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal.

More on this story

Amgen wins biosimilars case against Apotex at Federal Circuit

6 July 2016 The US Court of Appeals for the Federal Circuit ruled yesterday in the Amgen v Apotex case that bisoimilars companies must always notify brand name rivals 180 days before launching their products.

Sanofi victorious at Fed Circ in prostate cancer drug dispute

15 August 2019 Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.

Fresenius in patent dispute over hypocalcemia treatment

7 December 2021 Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal.

More on this story

Amgen wins biosimilars case against Apotex at Federal Circuit

6 July 2016 The US Court of Appeals for the Federal Circuit ruled yesterday in the Amgen v Apotex case that bisoimilars companies must always notify brand name rivals 180 days before launching their products.

Sanofi victorious at Fed Circ in prostate cancer drug dispute

15 August 2019 Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.

Fresenius in patent dispute over hypocalcemia treatment

7 December 2021 Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent